• Profile
Close

Pregabalin as adjunctive treatment for focal onset seizures in pediatric patients: A randomized controlled trial

Journal of Child Neurology Mar 22, 2019

Antinew J, et al. - In this investigation, researchers tested pregabalin as for safety and effectiveness as adjunctive treatment in children (aged 4-16 years) with partial-onset seizures, now called focal onset seizures. Criteria for inclusion was experiencing focal seizures and having a stable 1 to 3 antiepileptic drug regimen. Pregabalin 2.5 mg/kg/d, 10 mg/kg/d or placebo were used in the study, with doses increased to 3.5 or 14 mg/kg/d for subjects weighing <30 kg. Common adverse events included somnolence, increased weight and increased appetite. According to this double-blind, randomized, placebo-controlled, international study, pregabalin 10 mg/kg/d showed effectiveness in reducing seizure frequency in children with focal seizures vs placebo; both doses of pregabalin were generally safe and well tolerated.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay